
Adicet Bio, Inc.
- Jurisdiction
United States - LEI
549300VRD2QO80WBOP18 - ISIN
US0070021086 (ACET )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€108.26M - EBIT margin
0.0% - Net income
-€101.79M - Net margin
0.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
- Last dividend amount
-
$0.00 - Ex date
-
- Payment date
-
Earnings Calls
Latest earnings call: November 10, 2018
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |